Coverage
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets as it navigates a period of strategic and leadership transition.
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets, and forecast a similar performance for the year ahead as it implements a new strategy.
Coloplast interim Chief Executive Lars Rasmussen will step down from the company's board of directors, the latest leadership change at the Danish medical device maker as it implements a new strategy.
Danish medical device maker Coloplast on Tuesday unveiled a new five-year strategy that tempers its long-term growth forecast.
Danish medical device maker Coloplast on Tuesday tempered its long-term growth forecast as it unveiled a new five-year strategy, dubbed "Impact4."
Danish medical device maker Coloplast announced a significant overhaul of its executive team and corporate structure on Tuesday, moves it said are designed to support a new long-term strategy.
Filings
| Filing | Date |
|---|---|
| Coloplast, The Department of Health in the UK issues Consultation document | 2 Nov 2005 |
| Coloplast, financial calendar for 2005/06 | 25 Oct 2005 |
| Coloplast, date for 2004/05 Annual Report and Annual General Meeting | 25 Oct 2005 |
| Coloplast, insiders' tradings | 16 Sept 2005 |
| Coloplast, expansion of programme for buying back Coloplast’s own shares | 15 Sept 2005 |
| Coloplast, insiders' tradings | 6 Sept 2005 |
| Coloplast, insiders' tradings | 1 Sept 2005 |
| Coloplast, insiders' tradings | 23 Aug 2005 |
| Coloplast, insiders' tradings | 22 Aug 2005 |
| Coloplast, quarterly report Q3 | 19 Aug 2005 |
| Coloplast, Interim Financial Report, 2004/05 | 18 May 2005 |
| Coloplast, quarterly statement of shareholdings | 11 Mar 2005 |